革兰阴性菌血流感染的快速抗菌药物敏感性检测:FAST随机临床试验
FAST为开放标签随机临床试验,2023年12月至2025年5月在希腊、印度、以色列、西班牙7个医疗中心纳入革兰阴性杆菌血流感染住院成人和儿童患者,随机分为快速表型AST直接来自阳性血培养加标准药敏检测组(n=413)与单纯标准药敏检测组(n=437),所有患者均由本地抗菌药物管理团队审核并给出治疗建议。主要终点为30天DOOR三分类(无不良事件存活、有不良事件存活、死亡),快速检测组DOOR结局更可取的概率为48.8%(95%CI 45.3%-52.4%),未达优效。两组至有效抗生素治疗中位时间无差异,快速检测组至抗生素升级或降级中位时间快14小时(95%CI 6-22),其他次要终点无差异。在碳青霉烯耐药感染预设亚组中,快速检测组至有效治疗中位时间9.5小时 vs 标准检测组28小时(差值-18小时,95%CI -42至6)。
要点
- 主要终点30天DOOR:快速AST组结局更可取概率48.8%(95%CI 45.3%-52.4%),未超过50%优效界值,未优于标准检测。
- 快速AST组至抗生素升级或降级中位时间较标准检测组快14小时(95%CI 6-22),其他次要终点无差异。
- 碳青霉烯耐药感染预设亚组:快速AST组至有效治疗中位时间9.5小时 vs 标准组28小时(差值-18小时,95%CI -42至6)。
- 两组至有效抗生素治疗中位时间在按随机分组人群中无差异。
- 作者认为,结合其他疗效与安全性结局,这些发现可能有助于指导临床实践中快速药敏检测的使用。
适用人群与场景
- 住院成人和儿童患者,革兰阴性杆菌血流感染,来自希腊(n=2)、印度(n=1)、以色列(n=3)、西班牙(n=1)共7个医疗中心。
- 入组时间2023年12月至2025年5月,末次随访2025年6月18日。
处置流程与药物剂量
- 快速检测组:直接来自阳性血培养进行快速表型AST,加标准药敏检测(n=413)。
- 标准检测组:单纯标准药敏检测(n=437)。
- 所有患者均由本地抗菌药物管理团队审核并提供治疗建议。
研究设计与关键结果
- 开放标签随机临床试验,7个医疗中心,随机899例,850例纳入主要终点分析(中位年龄72岁,IQR 21岁;女性43%)。
- 主要终点30天DOOR:快速检测组结局更可取概率48.8%(95%CI 45.3%-52.4%),未达优效( superiority界值为95%CI下限超过50%)。
- 按随机分组人群:两组至有效抗生素治疗中位时间无差异。
- 按随机分组人群:快速检测组至抗生素升级或降级中位时间快14小时(95%CI 6-22)。
- 其他次要终点(30天死亡率、住院时长、ICU入住、医院获得性感染、3天内至有效抗生素治疗时间)两组无差异。
- 碳青霉烯耐药感染预设亚组:快速检测组至有效治疗中位时间9.5小时 vs 标准检测组28小时(差值-18小时,95%CI -42至6)。
证据类型、等级与局限
- 证据类型:开放标签随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在革兰阴性杆菌血流感染住院患者中,快速血培养AST未能在30天DOOR主要终点上优于标准检测,不能据此常规替代标准药敏检测。
- 快速AST可使抗生素升级或降级中位时间提前14小时(95%CI 6-22),但其他次要终点无差异。
- 在碳青霉烯耐药感染亚组中,快速AST组至有效治疗中位时间9.5小时 vs 标准组28小时(差值-18小时,95%CI -42至6,未达统计学显著),作者认为该发现可能有助于指导临床实践。
指南或共识出处
- ClinicalTrials.gov Identifier: NCT06174649
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Novel blood culture diagnostics provide rapid antimicrobial susceptibility testing (AST) results for bacteria causing bloodstream infections (BSIs) but have unclear clinical impact.
OBJECTIVE: To evaluate clinical outcomes of blood culture testing using a rapid AST method compared with standard AST in patients with BSIs caused by gram-negative bacilli in regions with high prevalence of antimicrobial resistance.
DESIGN, SETTING, AND PARTICIPANTS: Open-label randomized clinical trial that enrolled participants from December 2023 to May 2025 (final follow-up, June 18, 2025) at 7 medical centers in Greece (n = 2), India (n = 1), Israel (n = 3), and Spain (n = 1). Hospitalized patients (adults and children) with BSIs caused by gram-negative bacilli were eligible. Statistical analysis was conducted from August 2025 to January 2026.
INTERVENTION: Patients were randomized to undergo blood culture evaluation using rapid, phenotypic AST directly from positive blood cultures plus standard susceptibility testing (n = 413) vs standard susceptibility testing alone (n = 437). Local antimicrobial stewardship teams reviewed all patients and provided treatment recommendations.
MAIN OUTCOMES AND MEASURES: The primary outcome was a desirability of outcome ranking (DOOR) at day 30, with 3 categories (alive without deleterious events, alive with deleterious events, and death). The difference between rapid and standard testing was summarized as the probability that the DOOR outcomes were more desirable in the rapid testing group. Superiority was concluded if the lower limit of the 95% CI exceeded 50%. Secondary outcomes included 30-day mortality, length of hospitalization, intensive care unit admission, acquisition of hospital-acquired infections, time to effective antibiotic therapy within 3 days, and time to antibiotic escalation or deescalation within 3 days.
RESULTS: Of the 899 patients randomized, 850 were included in the primary outcome analysis (median [IQR] age, 72 [21] years; 43% female). The probability that DOOR outcomes were more favorable in the rapid testing group was 48.8% (95% CI, 45.3%-52.4%). Median time to effective antibiotic therapy was not different between the groups in the as-randomized population. Median time to antibiotic escalation or deescalation was faster in the rapid testing group by 14 hours (95% CI, 6-22) in the as-randomized population. There were no differences between the groups in other secondary outcomes. In the prespecified subgroup with carbapenem-resistant infections, median time to effective therapy was 9.5 hours in the rapid testing group vs 28 hours in the standard testing group (difference, -18 hours [95% CI, -42 to 6]).
CONCLUSIONS AND RELEVANCE: Among patients with gram-negative bacilli BSIs, rapid blood culture AST was not superior to standard testing by DOOR. When considered with other efficacy and safety outcomes, these findings may help inform the use of rapid susceptibility testing in clinical practice.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06174649.
参考来源
- Banerjee R, Komarow L, Li Y, et al. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical Trial. JAMA. 2026. PMID: 41999287. doi:10.1001/jama.2026.5487
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。